The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RULE 2.10 UPDATE

4 Nov 2015 18:28

RNS Number : 6200E
Plethora Solutions Holdings PLC
04 November 2015
 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

4 November 2015

RULE 2.10 UPDATE

In accordance with 2.10 of the City Code on Takeovers and Mergers (the "Code), the Company confirms that as at the date of this announcement, it has 823,297,686 ordinary shares of £0.01 each in issue with ISIN GB00B06GL868. Plethora's ordinary shares are listed on the Alternative Investment Market of the London Stock Exchange ("AIM").

In addition, Plethora has a number of warrants, convertible loans and options/share awards outstanding (none of which have an associated ISIN number). Details of these securities are included below.

Mellon Bridge Loans: a convertible loan note due to be repaid on 31 March 2010. Upon redemption, the loan may be converted to 17,000,000 ordinary shares of 1p at an exercise price of 2p per share.

Galloway loan warrant instrument: a warrant granted to Galloway Limited to subscribe for ordinary shares of 1p representing up to 5% of the fully diluted ordinary share capital (post exercise) at a price of 1.25p per share. The warrant is due to expire on 31 March 2023 and can be exercised at any point up to this date at the discretion of Galloway. Based on the current fully diluted ordinary share capital, the warrant allows Galloway to subscribe for up to 54,118,431 shares.

CfE loan warrant instrument: a warrant granted to the Capital for Enterprise fund to subscribe for ordinary shares of 1p representing up to 3% of the fully diluted ordinary share capital (post exercise) at a price of 1p per share. The warrant is due to expire on 31 March 2023 and can be exercised at any point up to this date at the discretion of Capital for Enterprise. Based on the current fully diluted ordinary share capital, the warrant allows Capital for Enterprise to subscribe for up to 32,471,058 shares.

Fundraising Warrants: warrants attached to the capital fundraising undertaken in September 2014. Up to 101,148,981 ordinary shares of 1p may be subscribed at an exercise price of 15p.

LTIPs: share awards under the Company's Long Term Incentive Plan. A total of 54,200,000 ordinary shares of 1p each will be awarded at no subscription cost to employees based on various commercial milestones. Additionally the LTIPs will automatically vest on a change of control of Plethora.

Executive Share Option Scheme (ESOP): available to all employees and directors of the Company. A total of 132,460 ordinary shares of 1p each may be issued in relation to the scheme at a subscription price of 59p per share.

 

Romero Tayong

Company Secretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RTTLLFFTLRLSIIE
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
30th Sep 20087:00 amRNSClinical Update - PSD502
11th Aug 20087:00 amRNSBoard Change
21st Jul 20082:20 pmRNSHolding(s) in Company
1st Jul 20087:05 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSChange of Adviser
27th Jun 20087:00 amRNSBoard Change
23rd Jun 20082:44 pmRNSAGM Statement
19th Jun 20087:00 amRNSClinical Update PSD502 Phase
22nd May 200810:00 amRNSAnnual Report and Accounts
29th Apr 20087:00 amRNSFinal Results
24th Apr 20087:00 amRNSClinical Update - PSD508
21st Apr 200811:13 amRNSNotice of Results
1st Apr 20087:01 amRNSRe $28m Financing
10th Mar 20085:49 pmRNSHolding(s) in Company
5th Feb 20087:00 amRNSClinical Update - PSD506
10th Jan 200810:39 amRNSChange of Registered Office
19th Dec 20077:01 amRNSClinical Update - PSD502
6th Dec 20077:00 amRNSClinical Update - PSD508
29th Nov 20077:01 amRNSClinical Update PSD503
30th Oct 200712:30 pmBUSSciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
30th Oct 20077:01 amRNSClinical Update PSD502 Ph III
8th Oct 20077:00 amRNSClinical Update PSD597
26th Sep 20077:02 amRNSInterim Results
25th Sep 20074:55 pmRNSHolding(s) in Company
10th Sep 20079:27 amRNSNotice of Results
6th Sep 20077:01 amRNSClinical Update PSD597
16th Aug 20072:44 pmRNSAIM Rule 26
12th Jul 20077:01 amRNSClinical Update - PSD502
10th Jul 20074:11 pmRNSResult of AGM
2nd Jul 20073:14 pmRNSDirector/PDMR Shareholding
2nd Jul 20077:01 amRNSProduct Update - Invicorp
29th Jun 20071:20 pmRNSTotal Voting Rights
29th Jun 200710:29 amRNSShare Options Award
25th Jun 20077:01 amRNSClinical Update PSD597 for IC
14th Jun 20074:46 pmRNSHolding(s) in Company
14th Jun 20074:39 pmRNSHolding(s) in Company
1st Jun 200710:00 amRNSDirectorate Change
30th May 20077:01 amRNSPreliminary Results
24th May 20071:00 pmBUSSciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation
24th May 20077:05 amRNSNotice of Results
24th May 20077:03 amRNSLicensing deal
8th May 20077:02 amRNSProduct Acquisitions
5th Apr 20077:36 amRNSAcquisition
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:04 pmRNSHolding(s) in Company
13th Mar 20071:08 pmRNSHolding(s) in Company
12th Mar 20072:16 pmRNSExercise of share options
1st Mar 20077:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.